MN SF4138

Establishes a formal definition of "covered insulin" as any validly prescribed drug containing insulin for diabetes treatment, excluding products labeled only for intravenous infusion.

Removes the previous requirement that insulin must be "self-administered on an outpatient basis" to qualify for the safety net program.

Exempts insulin products from the program if the wholesale acquisition cost is $8 or less per milliliter, adjusted annually for inflation.

Modifies manufacturer registration fee exemptions to reference "covered insulin" rather than "prescription insulin," with exemptions available for manufacturers with less than 5% of total Minnesota insulin sales or annual gross revenue under $2,000,000.

Repeals the program satisfaction survey requirement (subdivision 15) that had mandated the commissioner of health to survey individuals and pharmacies about their experience with the insulin safety net program.